Literature DB >> 32259678

Does the trihydrate of atorvastatin calcium possess a melting point?

Chaima Tizaoui1, Haykel Galai2, Maria Barrio3, Simon Clevers4, Nicolas Couvrat4, Valérie Dupray4, Gérard Coquerel4, Josep-Lluis Tamarit3, Ivo B Rietveld5.   

Abstract

To decide whether an active pharmaceutical ingredient can be used in its amorphous form in drug formulations, often the glass transition is studied in relation to the melting point of the pharmaceutical. If the glass transition temperature is high enough and found relatively close to the melting point, the pharmaceutical is considered to be a good glass former. However, it is obviously important that the observed melting point and glass transition involve exactly the same system, otherwise the two temperatures cannot be compared. Although this may seem trivial, in the case of hydrates, where water may leave the system on heating, the composition of the system may not be evident. Atorvastatin calcium is a case in point, where confusing terminology, absence of a proper anhydrate form, and loss of water on heating lead to several doubtful conclusions in the literature. However, considering that no anhydrate crystal has ever been observed and that the glass transition of the anhydrous system is found at 144 °C, it can be concluded that if the system is kept isolated from water, the chances that atorvastatin calcium crystallises at room temperature is negligible. The paper discusses the various thermal effects of atorvastatin calcium on heating and proposes a tentative binary phase diagram with water.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active pharmaceutical ingredient; Binary phase diagram; Glass transition; Hydrate; Kinetic stability; Thermal properties

Mesh:

Substances:

Year:  2020        PMID: 32259678     DOI: 10.1016/j.ejps.2020.105334

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  2 in total

1.  Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human.

Authors:  Mo'tasem M Alsmadi; Nour M Al-Daoud; Rana M Obaidat; Niazy A Abu-Farsakh
Journal:  AAPS PharmSciTech       Date:  2022-05-18       Impact factor: 3.246

2.  Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats.

Authors:  Carlos Torrado-Salmerón; Víctor Guarnizo-Herrero; Joana Henriques; Raquel Seiça; Cristina M Sena; Santiago Torrado-Santiago
Journal:  Pharmaceutics       Date:  2021-03-20       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.